Drugmaker Announces Promising Results of Potential Alzheimer's Treatment

Drugmaker Announces , Promising Results of Potential , Alzheimer's Treatment.

On September 28, shares of Biogen and other drugmakers researching Alzheimer's disease skyrocketed after Japan's Eisai Co.

Announced promising late-stage study results.

'Time' reports that the company said its potential treatment appeared to slow the progress of the fatal disease.

On September 27, Eisai announced the results of a global study of nearly 1,800 people with early-stage Alzheimer's.

According to the drugmaker, early results show that the treatment reduced patients' decline by 27% over 18 months.

Eisai Co.

Also announced plans to discuss the trial's full results at a conference in November.

'Time' reports that the company plans to publish the findings in a peer-reviewed medical journal.

Meanwhile, the company has already sought accelerated approval from the U.S. Food and Drug Administration.

'Time' reports that the regulatory agency is expected to make a decision by early 2023.

The Alzheimer's Association released a statement calling the study's findings the most encouraging to date for potential treatments.

Following the announcement, shares of Biogen Inc.

Jumped over 50% in premarket trading to top $300